Publications Dev

Publications

Scientific foundation of glycoengineering in biologics

Glyvantis Bio’s platform is supported by peer-reviewed research in antibody glycosylation, CHO cell metabolism and galactosylation control. These publications demonstrate how glycan structure influences antibody function, stability and clinical performance.

Glyvantis

  1. NEW! Computationally inspired glycoengineering to maximise mAb β4-galactosylation
  2. CHOmpact: a reduced metabolic model of Chinese hamster ovary cells with enhanced interpretability

Galactosylation as a major source of mAb variability

  1. Luo et al., 2026. Glycan profiles of FDA-approved therapeutic antibodies: insights from regulatory submissions. AAPS J 28, 53
  2. Raju et al., 2012. Galactosylation variations in marketed therapeutic antibodies. mAbs 4(3):385-391

Galactosylation enhances ADCC, CDC, and ADCP

  1. Khuns et al., 2020. Differential influence on antibody-dependent cellular phagocytosis by different glycoforms on therapeutic monoclonal antibodies. J Biotechnol 317:5-15
  2. Peschke et al., 2017. Fc-galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol 8:646
  3. Thomann et al., 2016. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol 73:69-75